Drug Sponsors

Roche will not extend offer for Illumina

Wednesday, April 18, 2012 11:00 AM

Roche has decided not to extend its tender offer for Illumina, based on preliminary estimates indicating the re-election of the incumbent directors of Illumina. Roche’s cash tender offer is due to expire on April 20, 2012 at 6 p.m. EST.

More... »

Eclipse wins exclusive worldwide antibody license from Dytax

Wednesday, April 18, 2012 09:58 AM

Burlington, Mass.-based biopharmaceutical company Dyax has granted Eclipse Therapeutics, a privately held oncology company of San Diego, exclusive worldwide license for the development and commercialization of preclinical fully-human antibodies discovered using Dyax's gold-standard phage display technology for use in oncology indications.

More... »

Vivia Biotech closes second round of funding for $9.4 million

Monday, April 16, 2012 03:21 PM

Vivia Biotech, a Spanish company focused on hematologic cancers, has successfully closed its second financing round of $9.4 million.

More... »

Lonza and Agennix to collaborate on talactoferrin

Monday, April 16, 2012 12:49 PM

Switzerland-based Lonza and Germany-based Agennix have signed an agreement for the production of Agennix’s talactoferrin.

More... »

Piramal nabs Bayer's molecular imaging development portfolio

Monday, April 16, 2012 12:18 PM

India-based Piramal Healthcare has acquired worldwide rights to Bayer Pharmaceuticals’ molecular imaging research and development portfolio through Piramal Imaging, its newly created subsidiary.

More... »

Vanda lands exclusive world-wide license for VLY-686 from Lilly

Monday, April 16, 2012 11:40 AM

Vanda Pharmaceuticals, a biopharmaceutical company focused on central nervous system disorders, has acquired an exclusive world-wide license from Eli Lilly to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.

More... »

Merck, Endocyte to develop and commercialize cancer drug vintafolide

Monday, April 16, 2012 10:55 AM

Merck has entered into an agreement with Endocyte, a biopharmaceutical company based in West Lafayette, Ind., to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145), which gained orphan drug status from the E.U. in March.

More... »

AstraZeneca and Conformetrix form collaboration

Monday, April 16, 2012 10:00 AM

Through a newly-formed research collaboration, Conformetrix, a company focused on optimizing drug discovery and design, will apply its proprietary NMR-based technology across AstraZeneca’s pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

More... »

Shire acquires Pervasis’ assets

Monday, April 16, 2012 09:47 AM

Shire Pharmaceuticals, a global specialty biopharmaceutical company, will acquire all the assets of Pervasis Therapeutics of Cambridge, Mass.

More... »

ImmunAid completes Round 1 funding for immune cycle concept

Friday, April 13, 2012 01:51 PM

ImmunAid, a private Australian-based biotech, has successfully completed its first capital raising over $1 million from independent arm's-length investors in the U.S., Europe and Australia.

More... »